Catalyst
Slingshot members are tracking this event:
Merrimack Pharma's (TEVA) Abbreviated New Drug Application (ANDA) for Generic Version of Janssen's (JNJ) Doxorubicin Accepted for Review by FDA
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TEVA |
|
|
JNJ |
|
|
Merrimack Pharmaceuticals |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 31, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Abbreviated New Drug Application, Generic Version, Doxorubicin, Doxil, Liposome Injection, Ovarian Cancer, Aids-related Kaposi's Sarcoma, Multiple Myeloma
